TD Cowen Downgrades Moderna (MRNA) to Market Perform; Stepping Back To The Sideline As COVID Settles & Before New Launches
Tweet Send to a Friend
TD Cowen analyst Tyler Van Buren downgraded Moderna (NASDAQ: MRNA) from Outperform to Market Perform with a price target of ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
